milyon88 click Critical Metals Corp. Appointment of CFO and Board TransitionArrests made after Kosovo blast called terrorism by premier

LAS VEGAS , Dec. 16, 2024 /PRNewswire/ -- CTLA-4 inhibitors are a well-established market in cancer care, and they are expected to grow significantly in the coming years. This is due to the expected label expansion and usage of the blockbuster YERVOY and an increasing number of new clinical studies evaluating better-acting versions of CTLA-4 inhibitors in various types of cancers. Other market drivers include increased usage of CTLA-4 inhibitors in combination with other immune checkpoint inhibitors and the increasing prevalence of cancer cases. DelveInsight's CTLA-4 Inhibitors Market Insights report includes a comprehensive understanding of current treatment practices, emerging CTLA-4 inhibitors, market share of individual therapies, and current and forecasted CTLA-4 inhibitors market size from 2020 to 2034, segmented into 7MM [ the United States , the EU4 ( Germany , France , Italy , and Spain ), the United Kingdom , and Japan ]. Key Takeaways from the CTLA-4 Inhibitors Market Report As per DelveInsight's analysis, the total market size of CTLA-4 inhibitors in the 7MM is expected to surge significantly by 2034. In 2023, YERVOY registered global sales of more than USD 2 billion , followed by IMJUDO which closed 2023 with more than USD 200 million in global sales. YERVOY in combination with OPDIVO is approved for multiple indications in first-line settings including metastatic Melanoma, mesothelioma, Renal Cell Carcinoma, NSCLC, Esophageal cancer, Gastric Cancer, and other second-line indications. There are other newer indications where the combo is being evaluated. Established CTLA-4 inhibitor companies include Bristol Myers Squibb (BMS) and AstraZeneca, Leading emerging CTLA-4 inhibitor companies such as Merck , Xilio therapeutics, BioNTech, Agenus, Bioatla OncoC4, and others are developing novel CTLA-4 inhibitors that can be available in the CTLA-4 inhibitors market in the coming years. Some of the key CTLA-4 inhibitors in the pipeline include Quavonlimab (MK-1308), gotistobart ( ONC-392/BN316 ), BA3071 , and others. Discover which therapies are expected to grab the CTLA-4 inhibitors market share @ CTLA-4 Inhibitors Market Report CTLA-4 Inhibitors Market Dynamics In recent years, the CTLA-4 inhibitors market has been shaped by significant advances in cancer immunotherapy. The growing use of combination therapies , particularly the pairing of CTLA-4 inhibitors with PD-1/PD-L1 inhibitors (like nivolumab or pembrolizumab), has transformed the treatment landscape for several cancers, including melanoma, renal cell carcinoma, and non-small cell lung cancer (NSCLC). This combination approach has demonstrated improved survival benefits , broadening the market for CTLA-4 inhibitors beyond their original monotherapy applications. Additionally, research is ongoing to explore the use of these drugs in other cancers such as colorectal and pancreatic cancer, further fueling market growth. However, market dynamics are influenced by several factors, including the high cost of immunotherapy treatments and the side effects associated with CTLA-4 inhibitors . Immune-related adverse events (irAEs) like colitis, hepatitis, and dermatitis are common due to the drug's effect of ramping up immune activity. As a result, healthcare providers are cautious in prescribing these treatments , and pharmaceutical companies are working on optimizing dosing regimens and exploring biomarkers that could predict which patients will respond best to CTLA-4 inhibition. These considerations impact pricing, regulatory approval, and overall market uptake. The competitive landscape is also heating up as more pharmaceutical companies enter the immunotherapy space. While Bristol- Myers Squibb's ipilimumab has dominated the market, new players and biosimilars are emerging. Additionally, research into next-generation CTLA-4 inhibitors and alternative immune checkpoint targets (like LAG-3 and TIGIT) could change the market dynamics further. The evolution and improvisation of this class can be seen through the development of Fc-enhanced tumor-activated anti-CTLA-4 inhibitors (Xilio's Therapeutics' Vilastobart) which also deplete regulatory T cells when activated (unmasked) in the tumor microenvironment (TME). The innovations in drug delivery and therapeutic combinations , is likely to drive new developments in this area, attracting substantial investment and strategic partnerships. Overall, the CTLA-4 inhibitors market remains highly promising, buoyed by the increasing global burden of cancer , the expanding role of immunotherapy in oncology, and the significant unmet need in the treatment of several aggressive cancers. Advances in research and clinical trials , along with ongoing regulatory approvals, are expected to keep this market growing in the foreseeable future. However, balancing efficacy, safety, and cost will be critical for both pharmaceutical companies and healthcare providers to ensure the sustained success of CTLA-4 inhibitors. CTLA-4 Inhibitors Treatment Market Approved CTLA-4 inhibitors at present are YERVOY (ipilimumab) and IMJUDO (tremelimumab-actl). In March 2011 , YERVOY was the first cancer immunotherapy approved for melanoma, specifically targeting CTLA-4. At that time, it was the only approved treatment for unresectable or metastatic melanoma that showed a significant enhancement in overall survival. The FDA's approval of YERVOY represents the result of over 14 years of research and development by BMS teams, as well as clinical trials involving 676 patients with unresectable or metastatic melanoma who had previously received one or more treatments, including aldesleukin, dacarbazine, temozolomide, fotemustine, or carboplatin, in a randomized Phase III clinical trial. IMJUDO is a human monoclonal antibody designed to inhibit the activity of CTLA-4. By blocking CTLA-4, it promotes T-cell activation, which enhances the immune response against cancer and encourages the destruction of cancer cells. With its initial regulatory approval, patients in the US suffering from unresectable liver cancer now have access to an approved dual immunotherapy treatment regimen that uniquely combines CTLA-4 inhibition with a PD-L1 inhibitor, thereby amplifying the immune response to their cancer. YERVOY currently leads the CTLA-4 inhibitor market, generating over USD 2 billion in sales in 2023, while IMJUDO ended the year with sales exceeding USD 200 million . However, numerous CTLA-4 inhibitors are in clinical trials, with some utilizing innovative proprietary technologies in their development, which could pose a significant challenge to YERVOY's market dominance in the future. Learn more about the FDA-approved CTLA-4 inhibitors @ CTLA-4 Inhibitors Drugs Key Emerging CTLA-4 Inhibitors and Companies Several key emerging players, including Merck, BioNTech, Agenus, BioAtla , and others, are involved in developing drugs for CTLA-4 inhibitors for various indications such as metastatic castration-resistant prostate cancer, breast cancer, cervical cancer, non-squamous cell lung cancer, and others. OncoC4/BioNTech's BNT316/ONC-392 (gotistobart) is a next-generation anti-CTLA-4 antibody being co-developed by BioNTech and OncoC4. It is in late-stage clinical trials, either as a monotherapy or in combination with other treatments, targeting various cancers including non-small cell lung cancer, ovarian cancer, high-grade serous adenocarcinoma of the ovary, primary peritoneal carcinoma, and fallopian tube cancer. CTLA-4 is an immune checkpoint receptor that suppresses T cell responses, limiting their ability to identify and destroy cancer cells. Gotistobart is designed to counteract this suppression while maintaining CTLA-4 recycling, which helps preserve T cell immunosuppressive function in peripheral tissues. This approach, now under clinical evaluation, aims to reduce immune-related side effects. BioAtla's BA3071 is a conditionally active biologic (CAB) anti-CTLA-4 antibody being developed as an immuno-oncology agent. It aims to provide efficacy comparable to existing anti-CTLA-4 antibodies, but with reduced toxicity due to its selective activity in the tumor microenvironment. While blocking CTLA-4 has been shown to enhance antitumor responses, it can also cause immune-related damage to healthy cells. To reduce this risk of on-target, off-tumor effects, BioAtla has used its proprietary CAB technology to ensure that BA3071 binds to the CTLA-4 receptor only on T cells within the tumor microenvironment. This design is intended to enhance both the efficacy and safety of anti-CTLA-4 therapy, whether used alone or in combination with other treatments, by activating T cells specifically in the tumor site. BA3071 is currently in Phase II trials for treating various solid tumors that respond to CTLA-4 inhibition in combination with a PD-1 blocking agent. The anticipated launch of these emerging therapies are poised to transform the CTLA-4 inhibitors market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the CTLA-4 inhibitors market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about CTLA-4 inhibitors clinical trials, visit @ CTLA-4 Inhibitors Treatment Drugs CTLA-4 Inhibitors Overview CTLA-4 inhibitors are a class of immune checkpoint inhibitors that target cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), a protein expressed in T cells. CTLA-4 plays a crucial role in downregulating immune responses by binding to B7 molecules on antigen-presenting cells (APCs), which suppresses T-cell activation. By inhibiting CTLA-4, these drugs block the suppression of T cells, thereby enhancing the immune system's ability to recognize and destroy cancer cells. This mechanism has made CTLA-4 inhibitors an essential part of cancer immunotherapy, particularly in treating advanced-stage malignancies like melanoma. Ipilimumab, the first approved CTLA-4 inhibitor, has shown significant survival benefits in clinical trials, leading to its use in combination with other immune checkpoint inhibitors, such as PD-1 inhibitors, to further improve patient outcomes. While CTLA-4 inhibitors have shown promise in cancer therapy, their use comes with challenges, particularly immune-related adverse events (irAEs). These adverse effects occur because the inhibition of CTLA-4 can lead to excessive immune activation, which may result in the immune system attacking normal tissues and organs. Common irAEs include colitis, dermatitis, and hepatitis. Managing these side effects requires a delicate balance between maintaining the anti-cancer immune response and mitigating harmful autoimmune reactions. Despite these challenges, the clinical benefits of CTLA-4 inhibitors have made them a vital component in the fight against cancer, driving ongoing research into their optimization and use in combination therapies. Scope of the CTLA-4 Inhibitors Market Report CTLA-4 Inhibitors Therapeutic Assessment: CTLA-4 Inhibitors current marketed and emerging therapies CTLA-4 Inhibitors Market Dynamics: Conjoint Analysis of Emerging CTLA-4 Inhibitors Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, CTLA-4 Inhibitors Market Access and Reimbursement Discover more about CTLA-4 inhibitors in development @ CTLA-4 Inhibitors Clinical Trials Table of Contents Related Reports Non-small Cell Lung Cancer Market Non-small Cell Lung Cancer Market Insight, Epidemiology and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NSCLC companies, including EMD Serono, Merck, Cellular Biomedicine Group, Inc., Celgene, CellSight Technologies, Inc., BeyondSpring Pharmaceuticals Inc., J Ints Bio, Forward Pharmaceuticals Co., Ltd., AstraZeneca, Bristol-Myers Squibb, Teligene US, Rain Oncology Inc, ReHeva Biosciences, Inc., Amgen, Novartis, RedCloud Bio, Parexel, Vitrac Therapeutics, LLC, Mythic Therapeutics, Instil Bio, Mirati Therapeutics Inc., Daiichi Sankyo, Inc., AstraZeneca, Precision Biologics, Inc, Promontory Therapeutics Inc., Palobiofarma SL, Regeneron Pharmaceuticals, Revolution Medicines, Inc., Cullinan Oncology, LLC, Iovance Biotherapeutics, Inc., Innate Pharma , among others. Non-small Cell Lung Cancer Pipeline Non-small Cell Lung Cancer Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key non-small cell lung cancer companies, including BridgeBio Pharma, Daiichi Sankyo, EMD Serono, Merck, BridgeBio Pharma, Abbvie, Pfizer, Eli Lilly and Company BioNTech SE, Shenzhen TargetRx, Taiho Pharmaceutical, Chong Kun Dang , Bristol Myers Squibb, Innovent Biologics, Xuanzhu Biopharmaceutical, Bayer, GeneScience Pharmaceuticals, InventisBio, Apollomics, Imugene, Ono Pharmaceutical, Pierre Fabre , Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb, Surface Oncology, Inhibrx, Sinocelltech, Mirati Therapeutics, REVOLUTION Medicines, Yong Shun Technology Development, Iovance Biotherapeutics, Galecto Biotech, among others. Ovarian Cancer Market Ovarian Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key ovarian cancer companies including Allarity Therapeutics, OSE Immunotherapeutic, Cristal Therapeutics, Bristol-Myers Squibb, Ono Pharmaceuticals, Merck & Co, Aravive Biologics, Mersana Therapeutics, Clovis Oncology, Verastem Oncology, Gradalis, VBL Therapeutics, AbbVie, Elevation oncology, OncoQuest Pharmaceuticals (CanariaBio), Alkermes, Hoffman-la Roche, AstraZeneca, MSD, GlaxoSmithKline, IMV, Corcept Therapeutics , among others. Ovarian Cancer Pipeline Ovarian Cancer Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key ovarian cancer companies, including Gradalis, VBL Therapeutics, AbbVie, Elevation oncology, OncoQuest Pharmaceuticals (CanariaBio), Alkermes, Hoffman-la Roche, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg SOURCE DelveInsight Business Research, LLP

How major US stock indexes fared Tuesday, 12/10/2024The National Health Insurance Authority (NHIA) has announced a significant milestone in the country’s healthcare sector, with 19.2 million Nigerians now enrolled into health insurance coverage. This figure represents a 14% increase from the previous baseline of 16.7 million, marking a remarkable achievement in the NHIA’s efforts to expand healthcare access to more Nigerians. Speaking at the end-of-year briefing with on Wednesday in Abuja, the Director General of NHIA, Dr. Kelechi Ohiri, noted that this achievement is a testament to the authority’s whole-of-government approach, which includes collaboration with state health insurance schemes and other stakeholders. While speaking further, the DG explained that initiatives such as Fistula Care Program, which offers free treatment for women suffering from obstetric fistula, and the SIGOP Program, designed to reduce maternal deaths by eliminating financial barriers during emergencies. ALSO READ: Sanwo-Olu distributes empowerment tools to vulnerable, indigent residents “When a woman is presented with a life-threatening obstetric complication, money must never be a barrier. We override the cost to ensure her survival and subsequent enrollment into health insurance.” He raised concerns about the challenges posed by Nigeria’s fragmented health insurance landscape, which includes 83 private insurers and 37 state health insurance agencies. He stressed the need to rebuild public trust, ensure regulatory compliance, and enhance awareness to encourage more Nigerians to enroll in health insurance programs. “Trust is key. Nigerians must be confident that when they are insured, they will receive the promised care. “The NHIA has increased capitation rates by 60% and professional fees by 40% to align with rising medical costs, while actuarial studies are being conducted to ensure premiums reflect industry best practices,” he stated. Looking ahead, NHIA has set ambitious goals for 2025, including, 20% increase in enrollment, leveraging state-of-the-art technology to streamline operations; Expanded access to Comprehensive Emergency Obstetric and Newborn Care (CEmONC) services in over 100 facilities nationwide. Collaborations with PenCom to provide health insurance for retirees, ensuring a safety net for this vulnerable group. “Our vision is to create a system where every Nigerian, irrespective of socioeconomic status, has access to quality healthcare,” Dr. Ohiri said. He highlighted plans to launch a fully digital platform to integrate enrollment, claims submission, and complaint management, enhancing efficiency and user experience. The NHIA has also signed MOUs with 11 hospitals and is working with key organizations, including the Society of Obstetricians and Gynecologists and the African Center for Population Health Policy, to ensure sustained progress. “We are not just building a scheme; we are building an authority that redefines healthcare delivery in Nigeria,” Dr. Ohiri emphasized. “Every reform we implement revolves around the patient’s needs.” Also speaking, the Acting Director of Enforcement, Dr Habib Abdulhameed, said, NHIA has made significant progress in its efforts to improve healthcare service delivery in Nigeria. He disclosed that a total of 2,591 complaints were received between January and October 2024, adding that out of these, 1,678 complaints were against healthcare providers, while 913 complaints were against the NHIA itself. He said, the Agency had achieved an 82% resolution rate for complaints received, as he attributed its success to its decentralized complaints handling system, which allows complaints to be handled at the state level. Abdulhameed also credited its robust monitoring and evaluation system, which enables it to track complaints and ensure that they are resolved promptly. “The NHIA’s complaints handling process involves several steps, including receipt of complaints, investigation, and resolution. The authority also imposes sanctions on healthcare providers that fail to meet its standards.” “In 2024, the NHIA imposed sanctions on several healthcare providers, including warnings, fines, and suspension. A total of 100 healthcare providers were sanctioned, with 97 cases resolved,” he added. NIGERIAN TRIBUNE

SAN FRANCISCO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Stitch Fix, Inc. SFIX , the leading online personal styling service, today announced its financial results for the first quarter of fiscal year 2025, ended November 2, 2024. "Our fiscal year is off to a strong start. We exceeded our expectations in the first quarter on the top and bottom lines," said Matt Baer, Chief Executive Officer, Stitch Fix. "Our clients are responding to the newness we have brought to our assortment as well as the improvements we've made to our client experience. This progress is a testament to the Stitch Fix team's ongoing execution of our transformation strategy, and we continue to expect to return to revenue growth by the end of FY26." During the first quarter of fiscal 2024, we ceased operations of our UK business and met the accounting requirements for reporting the UK business as a discontinued operation. Accordingly, our unaudited condensed consolidated financial statements reflect the results of the UK business as a discontinued operation for all periods presented. Unless otherwise noted, amounts and disclosures below relate to our continuing operations. First Quarter Fiscal 2025 Key Metrics and Financial Highlights Net revenue of $318.8 million, a decrease of 12.6% year-over-year. Active clients of 2,434,000, a decrease of 74,000, or 3.0%, quarter-over-quarter; and a decrease of 555,000, or 18.6%, year-over-year. Net revenue per active client ("RPAC") of $531, an increase of 4.9% year-over-year. Gross margin of 45.4%, an increase of 180 basis points year-over-year, which reflects improved transportation leverage and product margins. Net loss of $6.3 million and diluted loss per share of $0.05. Adjusted EBITDA of $13.5 million, which reflects continued cost management discipline. Net cash provided by operating activities of $14.3 million and free cash flow of $9.9 million in the first fiscal quarter. We ended the quarter with $253.3 million of cash, cash equivalents, and investments; and no debt. Financial Outlook Our financial outlook for the second quarter of fiscal 2025, ending February 1, 2025, is as follows: Q2 2025 Net Revenue $290 million – $300 million (12)% – (9)% YoY Adjusted EBITDA $8 million – $13 million 2.8% – 4.3% margin Our fiscal year is a 52-week or 53-week period ending on the Saturday closest to July 31. The fiscal year 2025 is a 52-week year and the fiscal year 2024 was a 53-week year, with the extra week occurring in the fourth quarter ending August 3, 2024. Our financial outlook for fiscal year 2025 is as follows: Fiscal Year 2025 Net Revenue $1.14 billion – $1.18 billion (15)% – (12)% YoY (13)% – (10)% YoY adjusted to a 52-week period (1) Adjusted EBITDA $25 million – $36 million 2.2% – 3.1% margin (1) Full fiscal year 2024 net revenue from continuing operations has been adjusted to remove the impact of the 53rd week for year-over-year comparative purposes. We expect both the second quarter and full fiscal year 2025 gross margin to be approximately 44% to 45%, and full fiscal year 2025 advertising expense as a percentage of revenue to be at the high end of an 8% to 9% range. Stitch Fix has not reconciled its Adjusted EBITDA outlook to GAAP net income (loss) because it does not provide an outlook for GAAP net income (loss) due to the uncertainty and potential variability of restructuring and other one-time costs, net other income (expense), provision for income taxes, and stock-based compensation expense, which are reconciling items between Adjusted EBITDA and GAAP net income (loss). Because Stitch Fix cannot reasonably predict such items, a reconciliation of the non-GAAP financial measure outlook to the corresponding GAAP measure is not available without unreasonable effort. We caution, however, that such items could have a significant impact on the calculation of GAAP net income (loss). For more information regarding the non-GAAP financial measures discussed in this release, please see "Non-GAAP Financial Measures" below. Conference Call and Webcast Information Matt Baer, Chief Executive Officer of Stitch Fix, and David Aufderhaar, Chief Financial Officer of Stitch Fix, will host a conference call at 2:00 p.m. Pacific Time today to discuss the Company's financial results and outlook. A live webcast of the call will be accessible on the investor relations section of the Stitch Fix website at https://investors.stitchfix.com . To access the call by phone, please register at the following link: Dial-In Registration: https://register.vevent.com/register/BIb75f616c9a2a4320adf40088c7b87810 Upon registration, telephone participants will receive the dial-in number along with a unique PIN number that can be used to access the call. A replay of the webcast will also be available for a limited time at https://investors.stitchfix.com . About Stitch Fix, Inc. Stitch Fix SFIX is the leading online personal styling service that helps people discover the styles they will love that fit perfectly so they always look - and feel - their best. Few things are more personal than getting dressed, but finding clothing that fits and looks great can be a challenge. Stitch Fix solves that problem. By pairing expert stylists with best-in-class AI and recommendation algorithms, the company leverages its assortment of exclusive and national brands to meet each client's individual tastes and needs, making it convenient for clients to express their personal style without having to spend hours in stores or sifting through endless choices online. Stitch Fix, which was founded in 2011, is headquartered in San Francisco. For more information, please visit https://www.stitchfix.com . Forward-Looking Statements This press release, the related conference call, and webcast contain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact could be deemed forward looking, including but not limited to statements regarding our expectations for future financial performance, including our profitability and long-term targets; guidance on financial results and metrics for the second quarter and full fiscal year of 2025; that the execution of our strategy and priorities will enable us to achieve long-term, sustainable, and profitable growth and positive free cash flow; our expectation to return to revenue growth by the end of fiscal year 2026; that the changes we have made to our client experience will help us acquire, retain, and reactivate highly engaged clients over time and better serve our clients; that our actions to make Stylists more visible to our clients will deepen relationships between clients and Stylists and increase client engagement; and our expectations regarding warehouse costs, transportation costs, gross margin, inventory levels, and advertising spend. These statements involve substantial risks and uncertainties, including risks and uncertainties related to the current macroeconomic environment; our ability to generate sufficient net revenue to offset our costs; consumer behavior; our ability to acquire, engage, and retain clients; our ability to provide offerings and services that achieve market acceptance; our data science and technology, Stylists, operations, marketing initiatives, and other key strategic areas; risks related to our inventory levels and management; risks related to our supply chain, sourcing of materials and shipping of merchandise; our ability to forecast our future operating results; and other risks described in the filings we make with the SEC. Further information on these and other factors that could cause our financial results, performance, and achievements to differ materially from any results, performance, or achievements anticipated, expressed, or implied by these forward-looking statements is included in filings we make with the SEC from time to time, including in the section titled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended August 3, 2024. These documents are available on the SEC Filings section of the Investor Relations section of our website at: https://investors.stitchfix.com . We undertake no obligation to update any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law. The achievement or success of the matters covered by such forward-looking statements involves known and unknown risks, uncertainties, and assumptions. If any such risks or uncertainties materialize or if any of the assumptions prove incorrect, our results could differ materially from the results expressed or implied by the forward-looking statements we make. You should not rely upon forward-looking statements as predictions of future events. Forward-looking statements represent our management's beliefs and assumptions only as of the date such statements are made. Stitch Fix, Inc. Condensed Consolidated Balance Sheets (Unaudited) (In thousands, except per share amounts) November 2, 2024 August 3, 2024 Assets Current assets: Cash and cash equivalents $ 137,153 $ 162,862 Short-term investments 116,119 84,106 Inventory, net 119,145 97,903 Prepaid expenses and other current assets 20,099 21,839 Total current assets 392,516 366,710 Property and equipment, net 49,204 51,517 Operating lease right-of-use assets 60,616 63,780 Other long-term assets 4,783 4,857 Total assets $ 507,119 $ 486,864 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 114,386 $ 87,058 Operating lease liabilities 21,999 21,817 Accrued liabilities 69,352 73,007 Gift card liability 6,296 6,749 Deferred revenue 9,256 9,217 Other current liabilities 5,232 5,201 Current liabilities, discontinued operations 32 502 Total current liabilities 226,553 203,551 Operating lease liabilities, net of current portion 89,465 95,685 Other long-term liabilities 606 606 Total liabilities 316,624 299,842 Stockholders' equity: Class A common stock, $0.00002 par value 1 1 Class B common stock, $0.00002 par value 1 1 Additional paid-in capital 694,339 684,650 Accumulated other comprehensive income (loss) (295 ) (335 ) Accumulated deficit (473,509 ) (467,253 ) Treasury stock, at cost (30,042 ) (30,042 ) Total stockholders' equity 190,495 187,022 Total liabilities and stockholders' equity $ 507,119 $ 486,864 Stitch Fix, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (In thousands, except share and per share amounts) For the Three Months Ended November 2, 2024 October 28, 2023 Revenue, net $ 318,818 $ 364,785 Cost of goods sold 174,013 205,682 Gross profit 144,805 159,103 Gross margin 45.4 % 43.6 % Selling, general, and administrative expenses 153,771 187,764 Operating loss (8,966 ) (28,661 ) Interest income 2,932 2,248 Other income (expense), net (72 ) 411 Loss before income taxes (6,106 ) (26,002 ) Provision for income taxes 157 169 Net loss from continuing operations (6,263 ) (26,171 ) Net income (loss) from discontinued operations, net of income taxes 7 (9,319 ) Net loss (6,256 ) (35,490 ) Other comprehensive income (loss): Change in unrealized gains and losses on available-for-sale securities, net of tax 40 121 Foreign currency translation — (1,129 ) Total other comprehensive income (loss), net of tax 40 (1,008 ) Comprehensive loss $ (6,216 ) $ (36,498 ) Loss per share from continuing operations, attributable to common stockholders: Basic $ (0.05 ) $ (0.22 ) Diluted $ (0.05 ) $ (0.22 ) Loss per share from discontinued operations, attributable to common stockholders: Basic $ 0.00 $ (0.08 ) Diluted $ 0.00 $ (0.08 ) Loss per share attributable to common stockholders: Basic $ (0.05 ) $ (0.30 ) Diluted $ (0.05 ) $ (0.30 ) Weighted-average shares used to compute loss per share attributable to common stockholders: Basic 125,972,658 116,645,160 Diluted 125,972,658 116,645,160 Stitch Fix, Inc. Condensed Consolidated Statements of Cash Flow (Unaudited) (In thousands) For the Three Months Ended November 2, 2024 October 28, 2023 Cash Flows from Operating Activities from Continuing Operations Net loss from continuing operations $ (6,263 ) $ (26,171 ) Adjustments to reconcile net loss from continuing operations to net cash provided by operating activities from continuing operations: Change in inventory reserves 4,970 3,083 Stock-based compensation expense 12,650 19,902 Depreciation, amortization, and accretion 6,859 13,784 Other 34 19 Change in operating assets and liabilities: Inventory (26,212 ) (33,255 ) Prepaid expenses and other assets 1,771 2,800 Operating lease right-of-use assets and liabilities (2,874 ) (1,349 ) Accounts payable 27,223 34,709 Accrued liabilities (3,507 ) 7,502 Deferred revenue 39 (664 ) Gift card liability (453 ) (503 ) Other liabilities 31 702 Net cash provided by operating activities from continuing operations 14,268 20,559 Cash Flows from Investing Activities from Continuing Operations Proceeds from sale of property and equipment — 21 Purchases of property and equipment (4,323 ) (3,653 ) Purchases of securities available-for-sale (46,074 ) — Sales of securities available-for-sale 2,468 — Maturities of securities available-for-sale 12,200 12,820 Net cash provided by (used in) investing activities from continuing operations (35,729 ) 9,188 Cash Flows from Financing Activities from Continuing Operations Payments for tax withholdings related to vesting of restricted stock units (3,785 ) (4,008 ) Other — (100 ) Net cash used in financing activities from continuing operations (3,785 ) (4,108 ) Net increase (decrease) in cash and cash equivalents from continuing operations (25,246 ) 25,639 Cash Flows from Discontinued Operations Net cash used in operating activities from discontinued operations (463 ) (6,119 ) Net cash used in financing activities from discontinued operations — (164 ) Net decrease in cash and cash equivalents from discontinued operations (463 ) (6,283 ) Effect of exchange rate changes on cash and cash equivalents — (1,895 ) Net increase (decrease) in cash and cash equivalents (25,709 ) 17,461 Cash and cash equivalents at beginning of period 162,862 239,437 Cash and cash equivalents at end of period $ 137,153 $ 256,898 Supplemental Disclosure Cash paid for income taxes $ 521 $ 386 Supplemental Disclosure of Non-Cash Investing and Financing Activities Purchases of property and equipment included in accounts payable and accrued liabilities $ 43 $ 1,099 Capitalized stock-based compensation $ 824 $ 1,303 Non-GAAP Financial Measures We report our financial results in accordance with generally accepted accounting principles in the United States ("GAAP"). However, management believes that certain non-GAAP financial measures provide users of our financial information with additional useful information in evaluating our performance. We believe that adjusted EBITDA from continuing operations ("Adjusted EBITDA") is frequently used by investors and securities analysts in their evaluations of companies, and that this supplemental measure facilitates comparisons between continuing operations of companies. We believe free cash flow from continuing operations ("Free Cash Flow") is an important metric because it represents a measure of how much cash from continuing operations we have available for discretionary and non-discretionary items after the deduction of capital expenditures. These non-GAAP financial measures may be different than similarly titled measures used by other companies. Our non-GAAP financial measures should not be considered in isolation from, or as substitutes for, financial information prepared in accordance with GAAP. There are several limitations related to the use of our non-GAAP financial measures as compared to the closest comparable GAAP measures. Some of these limitations include: Adjusted EBITDA excludes interest income and net other (income) expense as these items are not components of our core business; Adjusted EBITDA does not reflect our provision for income taxes, which may increase or decrease cash available to us; Adjusted EBITDA excludes the recurring, non-cash expenses of depreciation and amortization of property and equipment and, although these are non-cash expenses, the assets being depreciated and amortized may have to be replaced in the future; Adjusted EBITDA excludes the non-cash expense of stock-based compensation, which has been, and will continue to be for the foreseeable future, an important part of how we attract and retain our employees and a significant recurring expense in our business; Adjusted EBITDA excludes costs incurred related to discrete restructuring plans and other one-time costs attributable to our continuing operations that are fundamentally different in strategic nature and frequency from ongoing initiatives. We believe exclusion of these items facilitates a more consistent comparison of operating performance over time, however these costs do include cash outflows; and Free Cash Flow does not represent the total residual cash flow available for discretionary purposes and does not reflect our future contractual commitments. Adjusted EBITDA We define Adjusted EBITDA as net loss from continuing operations excluding interest income, net other (income) expense, provision for income taxes, depreciation and amortization, stock-based compensation expense, and restructuring and other one-time costs related to our continuing operations. The following table presents a reconciliation of net loss from continuing operations, the most comparable GAAP financial measure, to Adjusted EBITDA for each of the periods presented: For the Three Months Ended (in thousands) November 2, 2024 October 28, 2023 Net loss from continuing operations $ (6,263 ) $ (26,171 ) Add (deduct): Interest income (2,932 ) (2,248 ) Other (income) expense, net 72 (411 ) Provision for income taxes 157 169 Depreciation and amortization (1) 7,385 9,439 Stock-based compensation expense 12,650 19,902 Restructuring and other one-time costs (2) 2,425 7,950 Adjusted EBITDA $ 13,494 $ 8,630 (1) For the three months ended October 28, 2023, depreciation and amortization excluded $4.3 million reflected in "Restructuring and other one-time costs." (2) For the three months ended November 2, 2024, restructuring charges were $1.0 million in severance and employee-related benefits and other restructuring costs; and other-one time costs were $1.4 million in one-time bonuses for certain continuing employees. For the three months ended October 28, 2023, restructuring charges were $8.0 million in severance and employee-related benefits, accelerated depreciation, and other restructuring costs. Free Cash Flow We define Free Cash Flow as net cash flows provided by operating activities from continuing operations, reduced by purchases of property and equipment that are included in cash flows from investing activities from continuing operations. The following table presents a reconciliation of net cash flows provided by operating activities from continuing operations, the most comparable GAAP financial measure, to Free Cash Flow for each of the periods presented: For the Three Months Ended (in thousands) November 2, 2024 October 28, 2023 Free Cash Flow reconciliation: Net cash provided by operating activities from continuing operations $ 14,268 $ 20,559 Deduct: Purchases of property and equipment from continuing operations (4,323 ) (3,653 ) Free Cash Flow $ 9,945 $ 16,906 Net cash provided by (used in) investing activities from continuing operations $ (35,729 ) $ 9,188 Net cash used in financing activities from continuing operations $ (3,785 ) $ (4,108 ) Operating Metrics (in thousands) November 2, 2024 August 3, 2024 April 27, 2024 January 27, 2024 October 28, 2023 Active clients 2,434 2,508 2,633 2,805 2,989 Net Revenue per Active Client $ 531 $ 533 $ 525 $ 515 $ 506 Active Clients We define an active client as a client who checked out a Fix or was shipped an item via Freestyle in the preceding 52 weeks, measured as of the last day of that period. Clients check out a Fix when they indicate what items they are keeping through our mobile application or on our website. We consider each Women's, Men's, or Kids account as a client, even if they share the same household. Net Revenue per Active Client We calculate net revenue per active client based on net revenue over the preceding four fiscal quarters divided by the number of active clients measured as of the last day of the period. IR Contact: PR Contact: ir@stitchfix.com media@stitchfix.com © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.China is trying to wrap up every strata of British society in a clandestine network of spies penetrating industry, politics, commerce, technology, security and defence. If you counted everyone who has worked directly, or indirectly, for Chinese intelligence in the UK, it would likely run into tens of thousands. British intelligence has for years warned UK companies their research and development is extremely vulnerable to China’s spy agencies. Prince Andrew’s statement claiming never to have discussed anything of a “sensitive nature” with alleged Chinese spy Yang Tengbo is as ridiculous as it is arrogant. He could not know how much intelligence and access to important people a spy could glean from him, nor the true nature of their relationship. Just a subtle mention by a Chinese spy that they knew Prince Andrew could open doors. He is not interesting but the networks he has access to are very interesting to spies. If Yang is a spy, the naive Prince, who met Chinese President Xi Jinping in Beijing in 2018, likely became a passive agent who was inestimably valuable to Chinese intelligence – without realising it. A passive agent can be used to allow an actual agent to creep into a person’s contact network and then provide a gateway for other spies. And with technology of massive interest to China, that route could eventually lead to a technology contact worth millions. China has stolen technological research and development from the UK before – at a cost of hundreds of millions of pounds. The passive agent can also be persuaded to see another government’s point of view and perhaps change their behaviour and that of others towards a foreign government. For instance, a Chinese agent might persuade a passive agent that Beijing’s genocidal treatment of minority Uyghurs is justified. It is feared some people coming to the UK from China may have been asked by a spy agency to make friends or find out information. Head of MI5 Ken McCallum has warned at least 20,000 people had been approached by Chinese intelligence online in recent years. But for a senior royal not to be on his guard and to think he has done nothing wrong by hanging out with them is unfathomable.

Broncos' Zach Allen questionable for Sunday's game at Las Vegas, Brandon Jones to returnLast week, Republican Sen. Marsha Blackburn, Democrat Sen. Richard Blumenthal, and a legion of supporters of the stalled-out Kids Online Safety and Privacy Act ( ) rallied on Capitol Hill to urge the House to pass the landmark legislation, which was passed this summer by the Senate with a broad bipartisan 91-3 majority vote. Elon Musk, owner of X, and X CEO Linda Yaccarino have publicly endorsed the legislation, emphasizing the importance of protecting children online. Their support, along with that of many allies of President-elect Donald Trump, has intensified the pressure on House Republicans to advance the bill. U.S. Senate Committee on Commerce Chair Sen. Maria Cantwell and Ranking Member Sen. Ted Cruz, and Sens. Edward Markey, Bill Cassidy, Blumenthal, and Blackburn to House Republican leaders urging them to pass the bill before the end of the year. Thirty-two state attorneys general also sent a letter to congressional leadership urging them to pass the bill. KOSPA would enhance online protections for minors by imposing a “duty of care” on social media platforms to shield young users from harmful content. KOSPA combines two key pieces of legislation, the Children and Teens’ Online Privacy Protection Act ( 2.0) and the Kids Online Safety Act (KOSA). COPPA 2.0 bans online companies from collecting personal information from users under 17 without their consent and creates an eraser button to eliminate personal information online. KOSA provides children and parents with the tools, safeguards, and transparency to protect against online harms by establishing a duty of care for online platforms and requires the most protective settings for kids by default. Despite its strong bipartisan Senate approval, KOSA has encountered challenges in the House, where some Republicans say they are concerned about potential censorship and implications for free speech. To address these issues, last week Yaccarino collaborated with the bill’s authors to update its provisions with yet another of the bill that aims to alleviate Republicans’ fears of censorship. “We’ve heard the pleas of parents and youth advocates who seek sensible guardrails across online platforms, and the Kids Online Safety Act addresses that need,” Yaccarino said, adding that, “After working with the bill authors, I’m proud to share that we’ve made progress to further protect freedom of speech while maintaining safety for minors online. We urge Congress and the House to pass the Kids Online Safety Act this year.” “Led by X, the new changes ... strengthen the bill while safeguarding free speech online and ensuring it is not used to stifle expression,” Blackburn and Blumenthal said in a joint statement. “These changes should eliminate once and for all the false narrative that this bill would be weaponized by unelected bureaucrats to censor Americans. We thank Elon [Musk] and Linda [Yaccarino] for their bold leadership and commitment to protecting children online and for helping us get this bill across the finish line this Congress. We appreciate that this endorsement and revised text reflects their publicly stated goal of furthering free speech without fear of censorship. We reiterate X’s call to pass KOSA by the end of the year – it is clear that this legislation has overwhelming support from Congress.” Blackburn and Blumenthal said the “changes ... further make clear that KOSA would not censor, limit, or remove any content from the Internet, and it does not give the Federal Trade Commission or state Attorney Generals the power to bring lawsuits over content or speech, no matter who it is from.” Tennessee Attorney General Jonathan Skrmetti said, “we’ve seen firsthand how social media companies prioritize profits over our kids’ safety. While our offices individually pursue investigations and lawsuits against platforms like Meta and TikTok, we are glad to support the Senate’s bipartisan effort to empower our federal enforcement partners. KOSA provides additional tools to protect our children’s mental health from the negative effects of social media.” Critics, however, like the Electronic Frontier Foundation (EFF), say even the “last-minute draft remains, at its core, an unconstitutional censorship bill that threatens the online speech and privacy rights of all Internet users.” The advocacy group argues that “the most important update ... supposedly minimizes the impact of the bill on free speech. [But] as we’ve said before, KOSA’s duty of care section is its biggest problem, as it would force a broad swath of online services to make policy changes based on the content of online speech.” Catholic Association Senior Fellow Ashley McGuire said critics like the EFF “incorrectly assert that the bill would censor constitutionally protected speech and empower bureaucrats to prosecute innocent Americans. Instead, the bill would simply require technology companies to enact basic rules of play on their platforms.” With the current congressional session nearing its conclusion, the urgency for legislative action has intensified. But while the Senate’s decisive vote indicates significant bipartisan backing, the bill’s progression in the House remains uncertain. The limited time left in this session of Congress further complicates its prospects. House Speaker Mike Johnson has expressed ongoing concerns regarding free speech implications and potential government overreach and has indicated that while the bill’s objectives are commendable, it is crucial to ensure that the legislation does not inadvertently lead to censorship. The combination of legislative hesitations and time constraints poses significant hurdles to the bill’s passage before the current congressional session concludes. While the bill addresses critical issues regarding children’s online safety and has garnered substantial support, its enactment remains uncertain. However, with support from key Republicans and Trump allies, there’s still time for backers of the legislation to vote on the bill in the House. | | | | |